FEMINISEPNCT05754593
Study of Ovarian Reserve Concerning Patients With Multiple Sclerosis (MS), Compared to a Control Group
StatusRecruiting
PhaseNot applicable
Primary completion (estimated)
At risk: Primary completion moved at least 11 months later.
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 6 versions: 5 with changes below, 1 re-verified with no change. See every version on ClinicalTrials.gov ↗
- Notable Primary and study completion pushed from Dec 2026 to Dec 2027
- Eligibility criteria expanded, about 12 words
- Site contact updated
- Notable Primary and study completion dates: Dec 2025 to Dec 2026
- Study description revised
- Notable Trial status: Not Yet Recruiting to Recruiting
- Primary and study completion dates: Apr 2025 to Dec 2025
- Start date changed from estimate of Apr 2023 to Dec 4, 2023
- Site details revised
- Minor Study title revisedv2
- Study First Submitted
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Measure of Anti-Mullerian hormone (AMH) level by blood sample to compare ovarian reserve between patients with multiple sclerosis versus healthy controls from 25 to 35 years old.
Timeframe: At baseline (day 0)
Secondary (1)
Measure of Antral follicle count (AFC) by ultrasound imaging to compare ovarian reserve between patients with multiple sclerosis versus healthy controls from 25 to 35 years old.
Arms and interventions
MS patientsExperimental
Diagnosis of multiple sclerosis based on McDonald Criteria 2017
ControlsActive comparator
Healthy controls
Biologicals: Anti-Mullerian hormone (AMH) level
Other: Antral follicle count (AFC), Clinical assessment
Sites
1 site in 1 country
- CHU de Bordeaux - service de neurologieBordeaux, France